The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer.
Darren Sigal
No relevant relationships to disclose
Stephen G Marcus
No relevant relationships to disclose
Peter J. Rosen
No relevant relationships to disclose
Steven J. Cohen
No relevant relationships to disclose
Peter Lee
No relevant relationships to disclose
Timmy Nguyen
No relevant relationships to disclose
Thomas Edward Gribbin
No relevant relationships to disclose
Pedro Quintana Diez
No relevant relationships to disclose
Mitesh J. Borad
No relevant relationships to disclose